tetano
Editor, Senior Moderator
Sci Transl Med
. 2022 Jun 9;eabn3041.
doi: 10.1126/scitranslmed.abn3041. Online ahead of print.
The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
Robert J Benschop[SUP] #[/SUP][SUP] 1 [/SUP], Jay L Tuttle[SUP] #[/SUP][SUP] 1 [/SUP], Lin Zhang[SUP] 1 [/SUP], Josh Poorbaugh[SUP] 1 [/SUP], Nicole L Kallewaard[SUP] 1 [/SUP], Peter Vaillancourt[SUP] 1 [/SUP], Melissa Crisp[SUP] 1 [/SUP], Thi Ngoc Vy Trinh[SUP] 1 [/SUP], Joshua J Freitas[SUP] 1 [/SUP], Stephanie Beasley[SUP] 1 [/SUP], Montanea Daniels[SUP] 1 [/SUP], Natalie Haustrup[SUP] 1 [/SUP], Richard E Higgs[SUP] 1 [/SUP], Ajay Nirula[SUP] 1 [/SUP], Myron S Cohen[SUP] 2 [/SUP], Mary Marovich[SUP] 3 [/SUP]
Affiliations
Abstract
As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serological study evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study. Over the course of six months, serum samples were collected from a population of nursing home residents and staff enrolled in a clinical trial who were randomized to either bamlanivimab treatment or placebo. In an unplanned component of this trial, a subset of these participants was subsequently fully vaccinated with two doses of either SpikeVax (Moderna) or Comirnaty (BioNTech/Pfizer) COVID-19 mRNA vaccines. This post-hoc analysis assessed the immune response to vaccination for 135 participants without prior SARS-CoV-2 infection. Antibody titers and potency were assessed using three assays against SARS-CoV-2 proteins that bamlanivimab does not efficiently bind to, thereby reflecting the endogenous antibody response. All bamlanivimab and placebo recipients mounted a robust immune response to full COVID-19 vaccination, irrespective of age, risk-category, and vaccine type with any observed differences of uncertain clinical importance. These findings are pertinent for informing public health policy with results that suggest that the benefit of receiving COVID-19 vaccination at the earliest opportunity outweighs the minimal effect on the endogenous immune response due to prior prophylactic COVID-19 monoclonal antibody infusion.
. 2022 Jun 9;eabn3041.
doi: 10.1126/scitranslmed.abn3041. Online ahead of print.
The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
Robert J Benschop[SUP] #[/SUP][SUP] 1 [/SUP], Jay L Tuttle[SUP] #[/SUP][SUP] 1 [/SUP], Lin Zhang[SUP] 1 [/SUP], Josh Poorbaugh[SUP] 1 [/SUP], Nicole L Kallewaard[SUP] 1 [/SUP], Peter Vaillancourt[SUP] 1 [/SUP], Melissa Crisp[SUP] 1 [/SUP], Thi Ngoc Vy Trinh[SUP] 1 [/SUP], Joshua J Freitas[SUP] 1 [/SUP], Stephanie Beasley[SUP] 1 [/SUP], Montanea Daniels[SUP] 1 [/SUP], Natalie Haustrup[SUP] 1 [/SUP], Richard E Higgs[SUP] 1 [/SUP], Ajay Nirula[SUP] 1 [/SUP], Myron S Cohen[SUP] 2 [/SUP], Mary Marovich[SUP] 3 [/SUP]
Affiliations
- PMID: 35679357
- DOI: 10.1126/scitranslmed.abn3041
Abstract
As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serological study evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study. Over the course of six months, serum samples were collected from a population of nursing home residents and staff enrolled in a clinical trial who were randomized to either bamlanivimab treatment or placebo. In an unplanned component of this trial, a subset of these participants was subsequently fully vaccinated with two doses of either SpikeVax (Moderna) or Comirnaty (BioNTech/Pfizer) COVID-19 mRNA vaccines. This post-hoc analysis assessed the immune response to vaccination for 135 participants without prior SARS-CoV-2 infection. Antibody titers and potency were assessed using three assays against SARS-CoV-2 proteins that bamlanivimab does not efficiently bind to, thereby reflecting the endogenous antibody response. All bamlanivimab and placebo recipients mounted a robust immune response to full COVID-19 vaccination, irrespective of age, risk-category, and vaccine type with any observed differences of uncertain clinical importance. These findings are pertinent for informing public health policy with results that suggest that the benefit of receiving COVID-19 vaccination at the earliest opportunity outweighs the minimal effect on the endogenous immune response due to prior prophylactic COVID-19 monoclonal antibody infusion.